I highly doubt Ariad will have to worry about that projected profitability date of 2018:
0709 GMT Sanofi will keep looking for potential acquisition targets after it lost a bidding war for Medivation to rival Pfizer, says Bryan Garnier. "Obviously, the company won't call it a day and will continue to look for other potential targets in the field (and preferably profitable ones, with a promising development pipeline)," it says. Bryan Garnier says Regeneron, Incyte, Ariad or BioMarin are potential targets. It rates the shares at neutral with a target price at EUR83. Shares little changed at EUR69.55. (inti.landauro@wsj.com) Contact us in London. +44-20-7842-9464 markettalk@wsj.com (END) Dow Jones Newswires August 23, 2016 03:09 ET (07:09 GMT) Copyright (c) 2016 Dow Jones & Company, Inc.
